The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
- DOI
- 10.3389/fphar.2022.1015510
- Published
- 2022-09-30
- Container
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2022.1015510,
title = {The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy},
author = {Changjing Cai and Qingqing Luo and Yihan Liu and Yinghui Peng and Xiangyang Zhang and Zhaohui Jiang and Ziyang Feng and Yaru Qi and Yan Gao and Yongting Liu and Ping Liu and Yihong Chen and Cao Guo and Hong Shen and Shan Zeng and Ying Han},
year = {2022},
journal = {Frontiers in Pharmacology},
doi = {10.3389/fphar.2022.1015510},
url = {https://doi.org/10.3389/fphar.2022.1015510}
}RIS
TY - JOUR TI - The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy AU - Changjing Cai AU - Qingqing Luo AU - Yihan Liu AU - Yinghui Peng AU - Xiangyang Zhang AU - Zhaohui Jiang AU - Ziyang Feng AU - Yaru Qi AU - Yan Gao AU - Yongting Liu AU - Ping Liu AU - Yihong Chen AU - Cao Guo AU - Hong Shen AU - Shan Zeng AU - Ying Han PY - 2022 JO - Frontiers in Pharmacology DO - 10.3389/fphar.2022.1015510 UR - https://doi.org/10.3389/fphar.2022.1015510 ER -
APA
Cai, C., Luo, Q., Liu, Y., Peng, Y., Zhang, X., Jiang, Z., Feng, Z., Qi, Y., Gao, Y., Liu, Y., Liu, P., Chen, Y., Guo, C., Shen, H., Zeng, S., & Han, Y. (2022). The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.1015510
Source records
- crossref · retrieved 2026-11-05T04:01:56.075Z